CA
NZ
UK
AU
IND
US
…
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Edwards Lifesciences develops and sells heart valves and hemodynamic monitoring systems, with a leading transcatheter aortic valve replacement (TAVR) platform and surgical valve portfolio. Long-term growth may be supported by aging populations, expanding clinical indications for TAVR, international adoption and ongoing product innovation. Investors may find it attractive due to market leadership in structural heart disease and recurring revenue from procedure-related consumables.
Key risks include regulatory and reimbursement setbacks, competition from other device makers, variability in procedural adoption, and clinical trial or outcome setbacks; investors should monitor these factors.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1272.90M | 1548.10M | 1598.10M | 1767.40M | 1702.00M |
| Minority interest | 4.10M | 4.90M | 3.00M | - | - |
| Net income | 1073.50M | 4174.60M | 1402.40M | 1521.90M | 1503.10M |
| Selling general administrative | 2085.20M | 1789.20M | 1755.60M | 1567.60M | 1493.70M |
| Selling and marketing expenses | - | - | 1.20M | - | - |
| Gross profit | 4740.70M | 4322.00M | 4625.00M | 4302.00M | 3983.60M |
| Reconciled depreciation | 156.60M | 155.20M | 143.60M | 139.60M | 134.80M |
| Ebit | 1272.90M | 1567.90M | 1534.10M | 1748.50M | 1348.50M |
| Ebitda | 1429.50M | 1723.10M | 1534.10M | 1829.90M | 1483.30M |
| Depreciation and amortization | 156.60M | 155.20M | 144.90M | 81.40M | 134.80M |
| Non operating income net other | - | - | - | 38.10M | 30.10M |
| Operating income | 1636.20M | 1378.70M | 1534.10M | 1748.50M | 1348.50M |
| Other operating expenses | 4431.40M | 4060.80M | 4276.20M | 3593.20M | 3645.70M |
| Interest expense | 20.40M | 19.80M | 17.60M | 19.20M | 18.40M |
| Tax provision | 216.90M | 152.10M | 207.60M | 245.50M | 198.90M |
| Interest income | 148.40M | 120.30M | 67.20M | 16.30M | 1.00M |
| Net interest income | 148.40M | 100.50M | 40.70M | 16.30M | -1.00M |
| Extraordinary items | 13.40M | 2773.70M | 179.40M | - | - |
| Non recurring | - | - | - | 76.50M | 20.60M |
| Income tax expense | 216.90M | 152.10M | 198.70M | 245.50M | 198.90M |
| Total revenue | 6067.60M | 5439.50M | 6004.80M | 5382.40M | 5232.50M |
| Total operating expenses | 3104.50M | 2943.30M | 2896.40M | 2512.80M | 2396.80M |
| Cost of revenue | 1326.90M | 1117.50M | 1379.80M | 1080.40M | 1248.90M |
| Total other income expense net | -363.30M | 169.40M | 64.00M | 18.90M | 353.50M |
| Net income from continuing ops | 1056.00M | 1396.00M | 1428.10M | 1521.90M | 1503.10M |
| Net income applicable to common shares | 1073.50M | 4174.60M | 1402.40M | 1521.90M | 1503.10M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 13697.20M | 13055.30M | 9363.20M | 8292.50M | 8502.60M |
| Intangible assets | 1128.20M | 1176.60M | 399.40M | 285.20M | 323.60M |
| Other current assets | 473.80M | 495.40M | 671.30M | 195.90M | 237.10M |
| Total liab | 3359.60M | 2992.40M | 2643.80M | 2485.80M | 2666.70M |
| Total stockholder equity | 10337.60M | 9998.40M | 6650.00M | 5806.70M | 5835.90M |
| Other current liab | 1534.50M | 856.00M | 879.40M | 311.00M | 3.90M |
| Common stock | 658.70M | 654.80M | 650.50M | 646.30M | 642.00M |
| Capital stock | 658.70M | 654.80M | 650.50M | 646.30M | 642.00M |
| Retained earnings | 14240.50M | 13167.00M | 8992.40M | 7590.00M | 6068.10M |
| Other liab | - | - | - | 797.60M | 969.60M |
| Good will | 1768.60M | 1776.70M | 1145.10M | 1164.30M | 1167.90M |
| Other assets | 1379.80M | 1724.50M | 1218.30M | 783.10M | 357.50M |
| Cash | 2938.50M | 3045.20M | 1132.30M | 769.00M | 862.80M |
| Cash and equivalents | 2938.00M | 3045.20M | 1144.00M | 769.00M | 862.80M |
| Total current liabilities | 1813.70M | 1505.20M | 1195.40M | 1022.40M | 1032.30M |
| Current deferred revenue | 27.20M | 53.70M | 953.90M | 484.00M | 798.40M |
| Net debt | -2233.10M | -2345.20M | -447.20M | -77.70M | -172.50M |
| Short term debt | 24.50M | 23.40M | 22.90M | 25.50M | 25.50M |
| Short long term debt total | 705.40M | 700.00M | 685.10M | 691.30M | 690.30M |
| Other stockholder equity | -4323.30M | -3578.90M | -2750.10M | -2174.70M | -716.50M |
| Property plant equipment | 1914.60M | 1784.20M | 1843.40M | 1725.10M | 1638.70M |
| Total current assets | 6738.90M | 6285.40M | 4035.70M | 3095.80M | 3180.70M |
| Long term investments | 278.60M | 307.90M | 583.90M | 1239.00M | 1834.20M |
| Net tangible assets | - | - | - | 4357.20M | 4344.40M |
| Short term investments | 1288.30M | 930.70M | 500.50M | 446.30M | 604.00M |
| Net receivables | 912.10M | 727.40M | 828.10M | 699.10M | 664.90M |
| Long term debt | 598.30M | 597.70M | 597.00M | 596.30M | 595.70M |
| Inventory | 1126.20M | 1086.70M | 903.50M | 875.50M | 726.70M |
| Accounts payable | 227.50M | 197.40M | 186.60M | 201.90M | 204.50M |
| Accumulated other comprehensive income | -238.30M | -244.50M | -242.80M | -254.90M | -157.70M |
| Common stock total equity | - | - | - | 646.30M | 642.00M |
| Retained earnings total equity | - | - | - | 7590.00M | 6068.10M |
| Treasury stock | - | - | - | - | -2416.90M |
| Non currrent assets other | 234.90M | 732.40M | 774.30M | 299.10M | 110.80M |
| Non current assets total | 6958.30M | 6769.90M | 5327.50M | 5196.70M | 5321.90M |
| Capital lease obligations | 107.10M | 102.30M | 97.90M | 95.00M | 94.60M |
| Long term debt total | 598.30M | 597.70M | 597.00M | 596.30M | 595.70M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -282.10M | 2312.90M | 254.40M | 252.30M | -1335.20M |
| Change to liabilities | - | - | - | -27.00M | 257.20M |
| Total cashflows from investing activities | -712.90M | 2312.90M | 173.80M | 252.30M | -1722.50M |
| Net borrowings | - | - | -0.30M | -0.20M | -1.80M |
| Total cash from financing activities | -956.80M | -983.00M | -711.00M | -1584.50M | -356.30M |
| Change to operating activities | - | - | - | -96.90M | -39.80M |
| Net income | 1069.40M | 4169.70M | 1402.40M | 1521.90M | 1503.10M |
| Change in cash | -119.30M | 1910.80M | 375.40M | -94.80M | -332.80M |
| Begin period cash flow | 3058.80M | 1148.00M | 772.60M | 867.40M | 1200.20M |
| End period cash flow | 2939.50M | 3058.80M | 1148.00M | 772.60M | 867.40M |
| Total cash from operating activities | 1595.20M | 542.30M | 895.80M | 1218.20M | 1732.10M |
| Depreciation | 156.60M | 155.20M | 144.90M | 139.60M | 134.80M |
| Other cashflows from investing activities | -195.70M | 3745.30M | -75.00M | 517.10M | -61.50M |
| Dividends paid | - | - | 169.90M | - | - |
| Change to inventory | 50.70M | -256.10M | -289.00M | -213.40M | 19.00M |
| Change to account receivables | -23.00M | 121.20M | -141.20M | -84.10M | -112.40M |
| Sale purchase of stock | -893.40M | -1159.40M | -879.60M | -1727.10M | -512.80M |
| Other cashflows from financing activities | -237.50M | 176.40M | 168.90M | 142.80M | 163.50M |
| Change to netincome | - | - | - | -49.10M | -79.60M |
| Capital expenditures | 260.20M | 252.40M | 266.30M | 264.80M | 329.80M |
| Change receivables | - | - | - | -84.10M | -91.10M |
| Cash flows other operating | - | - | - | 1452.20M | 1491.80M |
| Cash and cash equivalents changes | - | - | - | -114.00M | -346.70M |
| Change in working capital | 154.60M | -259.30M | -526.30M | -421.40M | 145.30M |
| Stock based compensation | 158.10M | 162.30M | 139.40M | 126.80M | 109.30M |
| Other non cash items | 174.10M | -3362.20M | 7.50M | 105.80M | -119.00M |
| Free cash flow | 1335.00M | 289.90M | 629.50M | 953.40M | 1402.30M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences Corp |
0.26 0.29% |
90.82 | 45.03 | 27.40 | 7.63 | 4.54 | 7.16 | 29.96 |
| ABT Abbott Laboratories |
-1.78 1.70% |
103.10 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.84 0.89% |
93.95 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-4.71 1.54% |
301.42 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.55 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael A. Mussallem | Chairman & CEO | 1953 |
| Mr. Scott B. Ullem | Corp. VP & CFO | 1967 |
| Mr. Donald E. Bobo Jr. | Corp. VP of Strategy & Corp. Devel. | 1962 |
| Mr. Larry L. Wood | Corp. VP of Transcatheter Aortic Valve Replacement | 1966 |
| Mr. Jean-Luc Lemercier | Corp. VP of Europe, Middle East, Africa, Canada & Latin America | 1957 |
| Dr. Todd J. Brinton | Corp. VP of Advanced Technology & Chief Scientific Officer | NA |
| Mark Wilterding | VP of Investor Relations | NA |
| Mr. Arnold A. Pinkston | Corp. VP & Gen. Counsel | 1959 |
| Mr. Dirksen J. Lehman | Corp. VP of Public Affairs | NA |
| Ms. Christine Z. McCauley | Corp. VP of HR | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...